Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of VAY736 with or without lenalidomide in non-Hodgkin lymphoma
jRCT2031210238Phase 1Completed
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ianalumab in B-cell non-Hodgkin lymphoma (B-NHL) and diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Novartis. Primary endpoints: Incidence and nature of dose-limiting toxicities (DLTs), Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) and 2 more. Started Sep 2023; status: completed.
02
Drugs
ianalumab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2031210238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210238.